
|Videos|February 23, 2023
Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific
Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
5











































